Novo Nordisk
NVO
Market cap $214B

48.19 USD

+1.12

2.38%

At close Aug 1, 4:00 PM EDT

After hours

48.40

+0.21

0.44%

1 day

2.38%

5 days

-32.13%

1 month

-30.98%

3 months

-26.54%

6 months

-41.69%

Year to date

-44.94%

1 year

-63.62%

5 years

47.32%

10 years

59.99%

About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 77,406

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,327 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 617 | Existing positions reduced: 543

0.41% less ownership

Funds ownership: 9.95% [Q4 2024] → 9.54% (-0.41%) [Q1 2025]

9% less funds holding

Funds holding: 1,641 [Q4 2024] → 1,499 (-142) [Q1 2025]

23% less funds holding in top 10

Funds holding in top 10: 31 [Q4 2024] → 24 (-7) [Q1 2025]

24% less capital invested

Capital invested by funds: $30.1B [Q4 2024] → $22.9B (-$7.22B) [Q1 2025]

26% less call options, than puts

Call options by funds: $987M | Put options by funds: $1.34B

43% less first-time investments, than exits

New positions opened: 140 | Existing positions closed: 246

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NVO.

See Analyst Rankings

Financial journalist opinion

Based on 115 articles about NVO published over the past 30 days

The Motley Fool

Why Novo Nordisk Stock Bumped Higher on Friday

Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NVO 2.48%), understandably saw a stock price lift that day.

Why Novo Nordisk Stock Bumped Higher on Friday

The Score: Meta Platforms, Whirlpool, Novo Nordisk and More Stocks That Defined the Week

Here are some of the major companies whose stocks moved on the week's news.

The Score: Meta Platforms, Whirlpool, Novo Nordisk and More Stocks That Defined the Week

Weight-loss drugs may be coming to Medicare, Medicaid under experimental program

Costly GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound could be covered under the new plan

Weight-loss drugs may be coming to Medicare, Medicaid under experimental program

The Motley Fool

Why Novo Nordisk Stock Imploded This Week

Shares of Novo Nordisk (NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday.

Why Novo Nordisk Stock Imploded This Week

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) and reminds investors of the September 30, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Novo Nordisk A/S Securities and Sets a Lead Plaintiff Deadline of September 30, 2025

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) between May 7, 2025, to July 28, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Eric Barta v.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Novo Nordisk A/S Securities and Sets a Lead Plaintiff Deadline of September 30, 2025

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk stock sharply tanked this week, marking the pharmaceutical company's worst-ever weekly loss with a decline of more than 30% by Friday. This plunge extended the stock to its lowest point since August 2021, erasing nearly all gains made since the launch of its blockbuster weight-loss drug Wegovy.

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S NVO Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors.

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

See News Rankings

Charts implemented using Lightweight Charts™